June 9, 2010 / Intellect Neurosciences, Inc (OTCBB: ILNS) announced it has received a Notice of Allowance from the Israeli Patent and Trademark Office for a new patent related to the Company's clinical-stage drug candidate OX1 (OXIGON™), which has disease-modifying potential for Alzheimer's and other neurodegenerative disorders. OX1, which has been successfully tested by the Company in human Phase I safety trials, is an orally-administered, brain-penetrating, naturally-occurring copper-binding small molecule targeting multiple mechanisms that contribute significantly to the underlying pathology of Alzheimer's disease... Intellect Neurosciences' Press Release -
Thursday, July 1, 2010
Intellect Neurosciences : Notice of Allowance for Patent on Alzheimer's Drug from the Israeli Patent and Trademark Office
June 9, 2010 / Intellect Neurosciences, Inc (OTCBB: ILNS) announced it has received a Notice of Allowance from the Israeli Patent and Trademark Office for a new patent related to the Company's clinical-stage drug candidate OX1 (OXIGON™), which has disease-modifying potential for Alzheimer's and other neurodegenerative disorders. OX1, which has been successfully tested by the Company in human Phase I safety trials, is an orally-administered, brain-penetrating, naturally-occurring copper-binding small molecule targeting multiple mechanisms that contribute significantly to the underlying pathology of Alzheimer's disease... Intellect Neurosciences' Press Release -
